Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey

Department of Health Behavior, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA.
International Journal of Environmental Research and Public Health (Impact Factor: 2.06). 12/2011; 8(1):222-33. DOI: 10.3390/ijerph8010222
Source: PubMed


Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally.

Download full-text


Available from: Cheryl Rivard,
  • Source

    Addiction 09/2011; 106(9):1556-8. DOI:10.1111/j.1360-0443.2011.03531.x · 4.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigates the impact of visual and numerical representations of effectiveness and different lengths of follow-up upon the perceived effectiveness of stop smoking interventions. This study entails two between-subjects experiments with smokers from the general population. In Experiment 1, U.K. smokers (n = 318) viewed information about a stop smoking intervention that included (a) no effectiveness information, (b) standard numerical effectiveness information, or (c) numerical and visual absolute effectiveness information. In Experiment 2, U.K. smokers (n = 320) viewed numerical and visual absolute effectiveness information about a stop smoking intervention showing either the short-term (1-month) or the long-term (12-month) quit rate with and without intervention. Outcome measures included perceived effectiveness of stop smoking interventions and intentions to use them. In Experiment 1, numerical and visual absolute effectiveness information compared with no effectiveness information resulted in greater perceived effectiveness (Scheffé test, p = .033, Cohen's d = 0.36) and intentions to use stop smoking interventions (Scheffé test, p = .012, d = 0.43). No differences were detected between standard numerical effectiveness information and no effectiveness information. In Experiment 2, the short-term quit rate compared with long-term quit rate resulted in greater perceived effectiveness, t(318) = 3.2, p = .002, d = 0.35, but not significantly greater intentions to use stop smoking interventions, t(318) = 1.59, p = .11, d = 0.18. Presenting numerical and visual absolute effectiveness information about the short-term effectiveness of stop smoking interventions may increase the use of stop smoking interventions.
    Nicotine & Tobacco Research 11/2011; 14(2):200-8. DOI:10.1093/ntr/ntr197 · 3.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rates of smoking cessation have not changed in a decade, accentuating the need for novel approaches to prompt quit attempts. Within a nationwide randomized clinical trial (N = 849) to induce further quit attempts and cessation, smokers currently unmotivated to quit were randomized to a practice quit attempt (PQA) alone or to nicotine replacement therapy (hereafter referred to as nicotine therapy), sampling within the context of a PQA. Following a 6-week intervention period, participants were followed up for 6 months to assess outcomes. The PQA intervention was designed to increase motivation, confidence, and coping skills. The combination of a PQA plus nicotine therapy sampling added samples of nicotine lozenges to enhance attitudes toward pharmacotherapy and to promote the use of additional cessation resources. Primary outcomes included the incidence of any ever occurring self-defined quit attempt and 24-hour quit attempt. Secondary measures included 7-day point prevalence abstinence at any time during the study (ie, floating abstinence) and at the final follow-up assessment. Compared with PQA intervention, nicotine therapy sampling was associated with a significantly higher incidence of any quit attempt (49% vs 40%; relative risk [RR], 1.2; 95% CI, 1.1-1.4) and any 24-hour quit attempt (43% vs 34%; 1.3; 1.1-1.5). Nicotine therapy sampling was marginally more likely to promote floating abstinence (19% vs 15%; RR, 1.3; 95% CI, 1.0-1.7); 6-month point prevalence abstinence rates were no different between groups (16% vs 14%; 1.2; 0.9-1.6). Nicotine therapy sampling during a PQA represents a novel strategy to motivate smokers to make a quit attempt. Identifier: NCT00706979.
    Archives of internal medicine 11/2011; 171(21):1901-7. DOI:10.1001/archinternmed.2011.492 · 17.33 Impact Factor
Show more